Immutep Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 46

Employees

  • Stock Symbol
  • IMM

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.02
  • (As of Wednesday Closing)

Immutep General Information

Description

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Contact Information

Website
www.immutep.com
Formerly Known As
PBMD, Prima BioMed
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Level 32, Suite 32.07 Australia Square
  • 264 George Street
  • Sydney, New South Wales 2000
  • Australia
+61 (02)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • Level 32, Suite 32.07 Australia Square
  • 264 George Street
  • Sydney, New South Wales 2000
  • Australia
+61 (02)

Immutep Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immutep Stock Performance

As of 18-Nov-2026, Immutep’s stock price is $0.02. Its current market cap is $22.8M with 1.47B shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.02 $0.02 $0.01 - $0.32 $22.8M 1.47B 9.8M

Immutep Financials Summary

As of 30-Sep-2026, Immutep has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV (12,383) (13,635) 125,259 217,066
Revenue 9,861 0 0
EBITDA (54,038) (41,600) (29,036)
Net Income (53,723) (39,749) (27,994)
Total Assets 57,304 102,540 134,736
Total Debt 721 1,062 1,065
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immutep Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immutep‘s full profile, request access.

Request a free trial

Immutep Patents

Immutep Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-7306548-U Fastening element for two crossing beams Inactive 21-Feb-1973

Immutep Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immutep Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Immutep‘s full profile, request access.

Request a free trial

Immutep Acquisitions (1)

Immutep’s most recent deal was a Merger/Acquisition with Immutep (acquired) for . The deal was made on 17-Dec-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Immutep (acquired) 17-Dec-2014 Merger/Acquisition Drug Discovery
To view Immutep’s complete acquisitions history, request access »

Immutep ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Immutep’s complete esg history, request access »

Immutep FAQs

  • When was Immutep founded?

    Immutep was founded in 1987.

  • Where is Immutep headquartered?

    Immutep is headquartered in Sydney, Australia.

  • What is the size of Immutep?

    Immutep has 46 total employees.

  • What industry is Immutep in?

    Immutep’s primary industry is Drug Discovery.

  • Is Immutep a private or public company?

    Immutep is a Public company.

  • What is Immutep’s stock symbol?

    The ticker symbol for Immutep is IMM.

  • What is the current stock price of Immutep?

    As of 18-Nov-2026 the stock price of Immutep is $0.02.

  • What is the current market cap of Immutep?

    The current market capitalization of Immutep is $22.8M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process